International Clinical Trial: A Prospective Single-Arm Phase II Clinical Study of Glecirasib Combined with Sacituzumab Tirumotecan as Second-Line Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation

Geneva, July 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600127971) titled 'A Prospective Single-Arm Phase II Clinical Study of Glecirasib Combined with Sacituzumab Tirumotecan as Second-Line Therapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation' on July 10.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Peking Union Medical College Hospital

Condition: Histologically confirmed locally advanced (stage IIIB, IIIC ineligible for curative therapy) or metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC)

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-07-15

Target Sample S...